Low grade inflammation is notably by suppressed by conventional anti-inflammatory treatment: A randomised crossover trial

Heart

Volumn 90, Issue 7, 2004, Pages 804-805

  Perry, C G ^a   Cleland, S J ^a   Connell, J M ^a   Petrie, J R ^a   Sattar, N ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DEXAMETHASONE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART PROTECTION; HUMAN; MALE; METABOLIC DISORDER; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DEXAMETHASONE; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROCORTISONE; INFLAMMATION; MALE;

EID: 3042601061     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
2. Sattar N, Perry CG, Petrie JR. Type 2 diabetes as an inflammatory disorder. Br J Diabetes Vascular Dis 2003;3:36-41.
3. Jialal I, Stein D, Balis D, et al. S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.
4. van de Ree MA, Huisman MV, Princen HM, et al. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003;166:129-35.
5. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation Study. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-42.